Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SZSE:200028's Gross Margin % is ranked worse than 69.67% of 122
companies
in the Medical Distribution industry
Industry Median: 15.03
vs SZSE:200028: 10.36
China National Accord Medicines had a gross margin of 10.12% for the quarter that ended in Jun. 2026 => No sustainable competitive advantage
China National Accord Medicines (SZSE:200028) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
China National Accord Medicines had a gross margin of 10.12% for the quarter that ended in Jun. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
China National Accord Medicines Gross Margin % Related Terms
China National Accord Medicines Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China National Accord Medicines Gross Margin % Chart
SZSE:200028 vs MCK, COR, CAH: Gross Margin % Comparison
For the Medical Distribution subindustry, China National Accord Medicines's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China National Accord Medicines Gross Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China National Accord Medicines's Gross Margin % distribution charts can be found below:
* The bar in red indicates where China National Accord Medicines's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
China National Accord Medicines (SZSE:200028) has a Gross Margin % of 10.12% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on China National Accord Medicines and its competitors. This is 12% below median its historical median of 11.45. Over the past decade, China National Accord Medicines' Gross Margin % has ranged from 10.36 to 12.15. According to the industry distribution chart, China National Accord Medicines ranks #85 out of 122 companies in the Medical Distribution industry, placing it in the top 69.7%.
Is China National Accord Medicines' Gross Margin % too high?
China National Accord Medicines' current Gross Margin % of 10.12% is 12% below median its 10-year median of 11.45. Over the past 10 years, this metric has ranged from a low of 10.36 to a high of 12.15. The Medical Distribution industry median Gross Margin % is 15.03. China National Accord Medicines' value of 10.12% is 32.7% below this industry median. Based on the distribution chart, China National Accord Medicines ranks #85 out of 122 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, China National Accord Medicines has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Accord Medicines' Gross Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, China National Accord Medicines ranks #85 out of 122 companies for Gross Margin %. This places China National Accord Medicines in the lower half of its industry. The industry median Gross Margin % is 15.03. China National Accord Medicines' value of 10.12% is 32.7% below this benchmark. Historically, China National Accord Medicines' own Gross Margin % has ranged from 10.36 to 12.15 over the past decade. While the company's 10-year median is 11.45 vs. the industry median of 15.03, China National Accord Medicines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Distribution company?
The median Gross Margin % among Medical Distribution companies is 15.03, based on 122 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China National Accord Medicines's current Gross Margin % of 10.12% is 32.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on China National Accord Medicines and its competitors. For the Medical Distribution industry, the median Gross Margin % is 15.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China National Accord Medicines's current Gross Margin % is 10.12%, which is 12% below median its own 10-year median of 11.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Accord Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Accord Medicines (SZSE:200028) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$13.64, compared to a current price of HK$12.02 — trading 11.9% below its estimated fair value. The current Gross Margin % is 10.12%, which is 12% below median its 10-year median of 11.45 and 32.7% below the Medical Distribution industry median of 15.03. China National Accord Medicines' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For China National Accord Medicines (SZSE:200028), the current Gross Margin % is 10.12% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China National Accord Medicines (SZSE:200028) Overvalued in 2026?
Based on GuruFocus' analysis, China National Accord Medicines stock appears to be undervalued.
The current stock price of HK$12.02 is trading 11.9% below its estimated GF Value™ of HK$13.64.
GuruFocus considers China National Accord Medicines to be Modestly Undervalued.
Key valuation signals for SZSE:200028:
Gross Margin %: 10.12% (12% below median its 10-year median of 11.45)
GF Value™: HK$13.64 vs. price of HK$12.02 (11.9% below fair value)
Industry Position: 32.7% below the Medical Distribution median (#85 of 122)
No single metric tells the full story. See the SZSE:200028 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
82GF Score
Get the complete analysis for SZSE:200028
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:200028 has been successfully added to your 
